By implication, this finding raised the possibility that the 20 participants who did not have NGS results, and were considered as pathway non-altered in the expanded analysis on the basis of negative original genetic test results, might in fact have had PI3K/AKT/PTEN pathway-altered tumours; these participants amounted to 20 (31%) of 64 of the expanded pathway non-altered subgroup (ten had received capivasertib and ten had received placebo). Here, AKT1 is linked to neoplasm.